Antares Pharma Q3 Loss Narrows

(RTTNews) - Antares Pharma Inc. (ATRS) reported that its third-quarter net loss narrowed to $5.5 million or $0.03 per share from $6.1 million or $0.04 per share in the comparable period in 2016.

Total Revenue was $15.1 million for the three months ended September 30, 2017, compared to $13.5 million for the comparable period in 2016.

Total revenue represents revenue generated from sales of OTREXUP, Sumatriptan Injection USP, product sales of auto injectors and components, development and licensing revenue and royalties.

Product sales were $13.3 million for the three months ended September 30, 2017, compared to $11.1 million for the comparable period in 2016.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.03 per share and revenues of $13.96 million.